| |
IQVIA eCOA expert, Edward Bartels, walks through the capabilities and key features of the IQVIA eCOA platform. Watch the demo to explore functionalities from study design, eDiary and questionnaire design, and active study management.
|
|
Today’s Big NewsMay 13, 2024 |
| By James Waldron Takeda may be paring back its R&D pipeline in the name of efficiency, but the Japanese pharma has still found $100 million to ensure its clinical pipeline once again features an Alzheimer’s disease drug. |
|
|
|
By Nick Paul Taylor Sanofi is betting $80 million upfront on a GSK castoff ahead of a phase 3 readout. Fulcrum Therapeutics took the other side of the deal, handing Sanofi ex-U.S. rights to a rare disease candidate that is leading Roche in a race to market. |
By James Waldron Merck & Co. has bailed early on a phase 3 test of the anti-TIGIT antibody vibostolimab after a high rate of discontinuations rendered the trial's success unlikely. |
By Nick Paul Taylor Cytokinetics has set out to prove that aficamten is a threat to Bristol Myers Squibb’s $13.1 billion heart disease drug Camzyos, and a new analysis gives the first shot at an apples-to-apples comparison with late-phase data showing improvements in exercise capacity among patients. |
|
Identify more unique genes with a rapid workflow (< 5 hrs) and inputs down to 1 ng. Explore the data.
|
|
By Max Bayer OnKure is merging with publicly-listed Reneo, jumping onto Nasdaq and adding $65 million in PIPE cash. The focus is a lead PI3Kα inhibitor that entered the clinic in February. |
By Gabrielle Masson,Max Bayer We really didn't want to have to create another Layoff Tracker this year. But here we are, launching the third annual iteration tracking biopharma layoffs. |
By Gabrielle Masson,Annalee Armstrong,Max Bayer Welcome to Fierce Biotech's Fundraising Tracker, 2024's version. |
By Eric Sagonowsky Johnson & Johnson is again cutting its holdings in Kenvue. This time, it's pursuing a "debt-for-equity" offering that looks to be worth about $3.75 billion. |
By Conor Hale The Ethicon branch recalled its Mega Soft and Mega 2000 return electrodes in June 2023 after reports of injuries including third-degree burns. |
By Dave Muoio Four of the country's major health systems collectively paid their CEOs $62.6 million and their CFOs $25.6 million, both substantial increases over 2022. |
Fierce podcastsDon’t miss an episode |
| | This week’s episode of “The Top Line,” kicks off a series diving into the latest advancements in cell and gene therapy manufacturing. |
|
|---|
|
|
| WhitepaperPrecision collection of cell therapy source material doesn’t happen by chance. Our new whitepaper illuminates the science and strategies for successful apheresis. Sponsored by: Comprehensive Cell Solutions |
| WhitepaperLearn how Specifica’s in vitro antibody discovery platform can deliver better antibodies than traditional immunization approaches. Sponsored by: Specifica, a Q2 Solutions company |
| WhitepaperThis paper defines “digital companions” in biopharma, explores their value from the patient & company perspectives, & outlines a process for successfully fielding a new digital companion. Presented by: Blue Matter, strategic consultants in the life sciences |
| WhitepaperExplore the complex considerations of vaccine development for influenza and COVID-19, including the challenges posed by viral evolution and the importance of ongoing research in this paper by vaccine expert, Dr. Lisa Kierstead. Sponsored by: PPD®️ Laboratory Services |
| eBookTo make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time. Sponsored by: Emmes Company |
| WhitepaperDiscover the secrets behind successful patient engagement Sponsored by: ProofPilot |
| Whitepaper Antibody biomarkers are redefining precision medicine, from diagnosing diseases earlier to stratifying patients – download your copy today! Sponsored by: Sengenics Corporation LLC |
| Whitepaper The use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download now to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by: Lonza |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
